Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight, Raises Price Target to $22
Benzinga Newsdesk 11 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Wells Fargo analyst Derek Archila upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) from Equal-Weight to Overweight and raises the price target from $13 to $22.
Wells Fargo analyst Derek Archila upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) from Equal-Weight to Overweight and raises the price target from $13 to $22.